|
Changing Medicine Together!
|
Cannabis Patents
Cited Patent Filing date Publication date Applicant Title
US6410588B1 1998-04-14 2002-06-25 anti-inflammatory agents The Mathilda And Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
US20070099987A1 Treating or preventing diabetes with cannabidiol
US6630507 Autoimmune Disorders; Cannabiniods as antioxidants & neuroprotectants
1989 - Antiinflammatory and antimicrobial compounds and compositions
United States Patent 4837228.
US2304669 Aug 16, 1940 Dec 8, 1942 Adams Roger Isolation of cannabidiol
US4876276 Oct 26, 1987 Oct 24, 1989 Yissum Research Development Co. Of The Hebrew University Of Jerusalem(3S-4S)-7- hydroxy-Δ6 -tetrahydrocannabinols
US5227537 Jan 8, 1992Jul 13, 1993 Heinrich Mack Nachf. Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol
US5284867 Apr 8, 1992Feb 8, 1994 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA- blocking pharmaceutical compositions
US5434295 Feb 7, 1994Jul 18, 1995Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5462946 Mar 20, 1992Oct 31, 1995The United States Of America As Represented By The Department Of Health And Human Services Nitroxides as protectors against oxidative stress
US5512270 Aug 31, 1994Apr 30, 1996Duke University Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
US5521215 Feb 7, 1994May 28, 1996Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA- blocking pharmaceuticals
US5538993 Feb 7, 1994Jul 23, 1996Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5635530 Sep 11, 1992Jun 3, 1997Yissum Research Development Company Of The Hebrew University Of Jerusalem(3S,4S) -delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5696109 Jun 7, 1995Dec 9, 1997Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6410588 Apr 14, 1999Jun 25, 2002The Mathilda And Terence Kennedy Institute Of RheumatologyUse of cannabinoids as anti-inflammatory agents
EP0427518A1 Nov 6, 1990May 15, 1991Yissum Research Development Company Of The Hebrew University Of Jerusalem NMDA-Blocking compounds, pharmaceutical compositions, their preparation and use
EP0576357A1 Jun 23, 1993Dec 29, 1993SanofiPyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0656354A1 Nov 29, 1994Jun 7, 1995SanofiSubstituted N-piperidino 3-pyrazolecarboxamide
EP0658546A1 Dec 15, 1994Jun 21, 1995SanofiNovel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity
WO1993005031A1 Sep 11, 1992Mar 18, 1993Yissum Research Development Company Of The Hebrew University In Jerusalem ( 3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
WO1994012667A1 Nov 29, 1993Jun 9, 1994The United States Department Of The ArmyInhibitors of arachidonic acid metabolites for preventing neurological damage
WO1996012485A1 Oct 18, 1995May 2, 1996Eli Lilly And Company Treatment of disorders with duloxetine
WO1996018600A1 Dec 13, 1995Jun 20, 1996Lifegroup S.P.A. Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor
WO1997019063A1 Nov 21, 1996May 29, 1997SanofiPyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1999053917A1 *Apr 21, 1999Oct 28, 1999The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
* Cited by examiner
Non-Patent Citations
Reference
1 Agurell et al., "Pharmacokinetics and Metabolism of Delta<1>-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986).
2 Agurell et al., "Pharmacokinetics and Metabolism of Δ1-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986).
3 Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," J. Org. Chem., American Chemical Society, 62(2):417-421 (1997).
4 Carlini et al., "Hypnotic and Antielpileptic Effects of Cannabidiol," J. Clin. Pharmacol., 21:417S-427S (1981).
5 Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," Neuron, Cell Press, 1:623-634 (1988).
6 Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," Exp. Eye Res., Academic Press Inc., 39:251-259 (1984).
7 Colasanti et al., "Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol," Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984).
8 Combes et al. "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation," Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997).
9 Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," Experimental Neurology, Academic Press Inc., 70:626-637 (1980).
10 Consroe et al., "Antiepileptic Potential of Cannabidiol Analgos," J. Clin. Pharmacol., 21:428S-436S (1981).
11 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients<1>," Pharmacology, 21:175- 185 (1980).
12 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients1," Pharmacology, 21:175- 185 (1980).
13 Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," European Journal of Pharmacology, 283:19-29 (1995).
14 Hampson et al., "Cannabidiol and (-)Delta<9>-tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998).
15 Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998).
16 Hampson et al., "Cannabidiol and (−)Δ9-tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998).
17 Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,"NIDA Res. Monogr., 79:96-107 (1987).
18 Karler et al., "The Cannabinoids as Potential Antiepileptics," J. Clin. Pharmacol., 21:437S-448S (1981).
19 Mechoulam et al., "A Total Synthesis of d1-Delta<1>-Tetrahydrocannabinol, the Active Constituent of Hashish<1>," Journal of the American Chemical Society, 87:14:3273-3275 (1965).
20 Mechoulam et al., "Chemical Basis of Hashish Activity," Science, 18:611-612 (1970).
21 Mechoulam et al., "A Total Synthesis of d1-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish1," Journal of the American Chemical Society, 87:14:3273-3275 (1965).
22 Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," Acta Chem. Scand. B 31, 9:807-812 (1977).
23 Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," Drug Metabolism and Disposition, 16(3):469-472 (1988).
24 Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997).
25 Skaper et al., "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996).
26 Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," J. Clin. Pharmacol., 21:449S-463S (1981).
27 Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients," Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985).
28 *Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.*
29 Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," Arthritis & Rheumatism, 41(1):163-170 (1998).
* Cited by examiner
Referenced by
Citing Patent Filing date Publication date Applicant Title
US7179800 *Apr 15, 2003Feb 20, 2007Virginia Commonwealth University Cannabinoids
US7184198 *Mar 8, 2005Feb 27, 2007Konica Minolta Holdings, Inc. Display element
US7285687 Jun 20, 2002Oct 23, 2007Virginia Commonwealth University Cannabinoids
US7597910 Aug 20, 2005Oct 6, 2009Slgm Medical Research Institute Compositions and methods for treating prostate disorders
US7674922 Sep 28, 2006Mar 9, 2010Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US7884133 *Sep 8, 2004Feb 8, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives
US8106244 May 16, 2011Jan 31, 2012Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US8372169 May 7, 2007Feb 12, 2013Plasco Energy Group Inc. Low temperature gasification facility with a horizontally oriented gasifier
US8628796 Dec 9, 2005Jan 14, 2014Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US8642645 Jan 30, 2012Feb 4, 2014Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
US9040580 *May 18, 2011May 26, 2015Braintropia Co., Ltd. Method for prevention or treatment of degenerative neurologial brain disorders
US9095554 Mar 17, 2014Aug 4, 2015Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US9095563 Sep 26, 2014Aug 4, 2015Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
US9220294 Apr 29, 2014Dec 29, 2015Timothy McCullough Methods and devices using cannabis vapors
US9254008 Dec 18, 2014Feb 9, 2016Timothy McCullough Drug delivery system and method
US9370164 Jun 17, 2015Jun 21, 2016Biotech Institute, Llc Breeding, production, processing and use of specialty Cannabis
US9380813 Dec 18, 2014Jul 5, 2016Timothy McCullough Drug delivery system and method
US9408986 Dec 4, 2015Aug 9, 2016Timothy McCullough Methods and devices using cannabis vapors
US9539295 Dec 4, 2015Jan 10, 2017Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
US9565865 Aug 6, 2015Feb 14, 2017Imbue LLC Method for making coffee products containing cannabis ingredients
US9642317 May 11, 2016May 9, 2017Biotech Institute, LLC. Breeding, production, processing and use of specialty cannabis
US9682032 Mar 14, 2014Jun 20, 2017Glia, Llc Cranial delivery of pharmaceuticals
US9763894 Dec 5, 2007Sep 19, 2017Virginia Commonwealth University Inflammation therapy
US9763991 Jun 13, 2014Sep 19, 2017Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
US9814695 Dec 29, 2015Nov 14, 2017Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment
US20050159449 *Apr 15, 2003Jul 21, 2005Virginia Commonwealth University Cannabinoids
US20050165259 *Jun 20, 2002Jul 28, 2005Virginia Commonwealth University Cannabinoids
US20050206994 *Mar 8, 2005Sep 22, 2005Konica Minolta Holdings, Inc. Display element
US20060160748 *Dec 20, 2005Jul 20, 2006Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US20060160888 *Dec 9, 2005Jul 20, 2006Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20070037890 *Aug 14, 2006Feb 15, 2007Virginia Commonwealth UniversityC annabinoids
US20070041994 *Aug 20, 2005Feb 22, 2007Slgm Medical Research Institute Compositions and methods for treating prostate disorders
US20070082954 *Sep 8, 2004Apr 12, 2007Raphael Mechoulam Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives
US20070093665 *Sep 28, 2006Apr 26, 2007Amr Technology, Inc. Process for production of delta-9- tetrahydrocannabinol
US20080112895 *Aug 6, 2007May 15, 2008Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080139635 *Dec 5, 2007Jun 12, 2008Virginia Common Wealth University Inflammation Therapy
US20080262079 *Aug 9, 2005Oct 23, 2008Bernard Mach Cannabinoid Compositions and Methods of Use Thereof
US20090181080 *Aug 6, 2008Jul 16, 2009Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US20090306221 *May 31, 2007Dec 10, 2009Gw Pharma Limited Use for Cannabinoid
US20090318526 *Jun 8, 2007Dec 24, 2009Uno Jacob Weber Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
US20100069651 *Nov 25, 2009Mar 18, 2010Albany Molecular Research, Inc. Process for production of delta-9- tetrahydrocannabinol
US20120302646 *Jul 31, 2012Nov 29, 2012University Of South Carolina Use of Cannabidiol in the Treatment of Hepatitis
US20130178527 *May 18, 2011Jul 11, 2013Braintropia Co., Ltd. Method for prevention or treatment of degenerative neurologial brain disorders
WO2009013506A1 *Jul 24, 2008Jan 29, 2009Gw Pharma Limited Cannabidiol for use in the treatment of transmissible neurodegenerative conditions
WO2010012506A1 *Jul 31, 2009Feb 4, 2010Bionorica Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2014152385A3 *Mar 14, 2014Dec 11, 2014Glia, Llc Cranial delivery of pharmaceuticals
WO2015140736A1 *Mar 18, 2015Sep 24, 2015Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
WO2016109531A1 *Dec 29, 2015Jul 7, 2016Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment
US6410588B1 1998-04-14 2002-06-25 anti-inflammatory agents The Mathilda And Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
US20070099987A1 Treating or preventing diabetes with cannabidiol
US6630507 Autoimmune Disorders; Cannabiniods as antioxidants & neuroprotectants
1989 - Antiinflammatory and antimicrobial compounds and compositions
United States Patent 4837228.
US2304669 Aug 16, 1940 Dec 8, 1942 Adams Roger Isolation of cannabidiol
US4876276 Oct 26, 1987 Oct 24, 1989 Yissum Research Development Co. Of The Hebrew University Of Jerusalem(3S-4S)-7- hydroxy-Δ6 -tetrahydrocannabinols
US5227537 Jan 8, 1992Jul 13, 1993 Heinrich Mack Nachf. Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol
US5284867 Apr 8, 1992Feb 8, 1994 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA- blocking pharmaceutical compositions
US5434295 Feb 7, 1994Jul 18, 1995Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5462946 Mar 20, 1992Oct 31, 1995The United States Of America As Represented By The Department Of Health And Human Services Nitroxides as protectors against oxidative stress
US5512270 Aug 31, 1994Apr 30, 1996Duke University Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
US5521215 Feb 7, 1994May 28, 1996Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA- blocking pharmaceuticals
US5538993 Feb 7, 1994Jul 23, 1996Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5635530 Sep 11, 1992Jun 3, 1997Yissum Research Development Company Of The Hebrew University Of Jerusalem(3S,4S) -delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5696109 Jun 7, 1995Dec 9, 1997Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6410588 Apr 14, 1999Jun 25, 2002The Mathilda And Terence Kennedy Institute Of RheumatologyUse of cannabinoids as anti-inflammatory agents
EP0427518A1 Nov 6, 1990May 15, 1991Yissum Research Development Company Of The Hebrew University Of Jerusalem NMDA-Blocking compounds, pharmaceutical compositions, their preparation and use
EP0576357A1 Jun 23, 1993Dec 29, 1993SanofiPyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0656354A1 Nov 29, 1994Jun 7, 1995SanofiSubstituted N-piperidino 3-pyrazolecarboxamide
EP0658546A1 Dec 15, 1994Jun 21, 1995SanofiNovel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity
WO1993005031A1 Sep 11, 1992Mar 18, 1993Yissum Research Development Company Of The Hebrew University In Jerusalem ( 3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
WO1994012667A1 Nov 29, 1993Jun 9, 1994The United States Department Of The ArmyInhibitors of arachidonic acid metabolites for preventing neurological damage
WO1996012485A1 Oct 18, 1995May 2, 1996Eli Lilly And Company Treatment of disorders with duloxetine
WO1996018600A1 Dec 13, 1995Jun 20, 1996Lifegroup S.P.A. Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor
WO1997019063A1 Nov 21, 1996May 29, 1997SanofiPyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1999053917A1 *Apr 21, 1999Oct 28, 1999The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
* Cited by examiner
Non-Patent Citations
Reference
1 Agurell et al., "Pharmacokinetics and Metabolism of Delta<1>-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986).
2 Agurell et al., "Pharmacokinetics and Metabolism of Δ1-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986).
3 Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," J. Org. Chem., American Chemical Society, 62(2):417-421 (1997).
4 Carlini et al., "Hypnotic and Antielpileptic Effects of Cannabidiol," J. Clin. Pharmacol., 21:417S-427S (1981).
5 Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," Neuron, Cell Press, 1:623-634 (1988).
6 Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," Exp. Eye Res., Academic Press Inc., 39:251-259 (1984).
7 Colasanti et al., "Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol," Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984).
8 Combes et al. "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation," Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997).
9 Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," Experimental Neurology, Academic Press Inc., 70:626-637 (1980).
10 Consroe et al., "Antiepileptic Potential of Cannabidiol Analgos," J. Clin. Pharmacol., 21:428S-436S (1981).
11 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients<1>," Pharmacology, 21:175- 185 (1980).
12 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients1," Pharmacology, 21:175- 185 (1980).
13 Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," European Journal of Pharmacology, 283:19-29 (1995).
14 Hampson et al., "Cannabidiol and (-)Delta<9>-tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998).
15 Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998).
16 Hampson et al., "Cannabidiol and (−)Δ9-tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998).
17 Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,"NIDA Res. Monogr., 79:96-107 (1987).
18 Karler et al., "The Cannabinoids as Potential Antiepileptics," J. Clin. Pharmacol., 21:437S-448S (1981).
19 Mechoulam et al., "A Total Synthesis of d1-Delta<1>-Tetrahydrocannabinol, the Active Constituent of Hashish<1>," Journal of the American Chemical Society, 87:14:3273-3275 (1965).
20 Mechoulam et al., "Chemical Basis of Hashish Activity," Science, 18:611-612 (1970).
21 Mechoulam et al., "A Total Synthesis of d1-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish1," Journal of the American Chemical Society, 87:14:3273-3275 (1965).
22 Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," Acta Chem. Scand. B 31, 9:807-812 (1977).
23 Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," Drug Metabolism and Disposition, 16(3):469-472 (1988).
24 Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997).
25 Skaper et al., "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996).
26 Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," J. Clin. Pharmacol., 21:449S-463S (1981).
27 Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients," Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985).
28 *Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.*
29 Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," Arthritis & Rheumatism, 41(1):163-170 (1998).
* Cited by examiner
Referenced by
Citing Patent Filing date Publication date Applicant Title
US7179800 *Apr 15, 2003Feb 20, 2007Virginia Commonwealth University Cannabinoids
US7184198 *Mar 8, 2005Feb 27, 2007Konica Minolta Holdings, Inc. Display element
US7285687 Jun 20, 2002Oct 23, 2007Virginia Commonwealth University Cannabinoids
US7597910 Aug 20, 2005Oct 6, 2009Slgm Medical Research Institute Compositions and methods for treating prostate disorders
US7674922 Sep 28, 2006Mar 9, 2010Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US7884133 *Sep 8, 2004Feb 8, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives
US8106244 May 16, 2011Jan 31, 2012Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US8372169 May 7, 2007Feb 12, 2013Plasco Energy Group Inc. Low temperature gasification facility with a horizontally oriented gasifier
US8628796 Dec 9, 2005Jan 14, 2014Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US8642645 Jan 30, 2012Feb 4, 2014Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
US9040580 *May 18, 2011May 26, 2015Braintropia Co., Ltd. Method for prevention or treatment of degenerative neurologial brain disorders
US9095554 Mar 17, 2014Aug 4, 2015Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US9095563 Sep 26, 2014Aug 4, 2015Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
US9220294 Apr 29, 2014Dec 29, 2015Timothy McCullough Methods and devices using cannabis vapors
US9254008 Dec 18, 2014Feb 9, 2016Timothy McCullough Drug delivery system and method
US9370164 Jun 17, 2015Jun 21, 2016Biotech Institute, Llc Breeding, production, processing and use of specialty Cannabis
US9380813 Dec 18, 2014Jul 5, 2016Timothy McCullough Drug delivery system and method
US9408986 Dec 4, 2015Aug 9, 2016Timothy McCullough Methods and devices using cannabis vapors
US9539295 Dec 4, 2015Jan 10, 2017Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
US9565865 Aug 6, 2015Feb 14, 2017Imbue LLC Method for making coffee products containing cannabis ingredients
US9642317 May 11, 2016May 9, 2017Biotech Institute, LLC. Breeding, production, processing and use of specialty cannabis
US9682032 Mar 14, 2014Jun 20, 2017Glia, Llc Cranial delivery of pharmaceuticals
US9763894 Dec 5, 2007Sep 19, 2017Virginia Commonwealth University Inflammation therapy
US9763991 Jun 13, 2014Sep 19, 2017Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
US9814695 Dec 29, 2015Nov 14, 2017Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment
US20050159449 *Apr 15, 2003Jul 21, 2005Virginia Commonwealth University Cannabinoids
US20050165259 *Jun 20, 2002Jul 28, 2005Virginia Commonwealth University Cannabinoids
US20050206994 *Mar 8, 2005Sep 22, 2005Konica Minolta Holdings, Inc. Display element
US20060160748 *Dec 20, 2005Jul 20, 2006Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US20060160888 *Dec 9, 2005Jul 20, 2006Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20070037890 *Aug 14, 2006Feb 15, 2007Virginia Commonwealth UniversityC annabinoids
US20070041994 *Aug 20, 2005Feb 22, 2007Slgm Medical Research Institute Compositions and methods for treating prostate disorders
US20070082954 *Sep 8, 2004Apr 12, 2007Raphael Mechoulam Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives
US20070093665 *Sep 28, 2006Apr 26, 2007Amr Technology, Inc. Process for production of delta-9- tetrahydrocannabinol
US20080112895 *Aug 6, 2007May 15, 2008Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080139635 *Dec 5, 2007Jun 12, 2008Virginia Common Wealth University Inflammation Therapy
US20080262079 *Aug 9, 2005Oct 23, 2008Bernard Mach Cannabinoid Compositions and Methods of Use Thereof
US20090181080 *Aug 6, 2008Jul 16, 2009Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US20090306221 *May 31, 2007Dec 10, 2009Gw Pharma Limited Use for Cannabinoid
US20090318526 *Jun 8, 2007Dec 24, 2009Uno Jacob Weber Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
US20100069651 *Nov 25, 2009Mar 18, 2010Albany Molecular Research, Inc. Process for production of delta-9- tetrahydrocannabinol
US20120302646 *Jul 31, 2012Nov 29, 2012University Of South Carolina Use of Cannabidiol in the Treatment of Hepatitis
US20130178527 *May 18, 2011Jul 11, 2013Braintropia Co., Ltd. Method for prevention or treatment of degenerative neurologial brain disorders
WO2009013506A1 *Jul 24, 2008Jan 29, 2009Gw Pharma Limited Cannabidiol for use in the treatment of transmissible neurodegenerative conditions
WO2010012506A1 *Jul 31, 2009Feb 4, 2010Bionorica Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2014152385A3 *Mar 14, 2014Dec 11, 2014Glia, Llc Cranial delivery of pharmaceuticals
WO2015140736A1 *Mar 18, 2015Sep 24, 2015Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
WO2016109531A1 *Dec 29, 2015Jul 7, 2016Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment
Further additional natural or synthetic cannabinoids are described in
U.S. Pat. Nos.
4,371,720, 5,013,387, 5,081,122, 5,292,736, 5,461,034, 5,618,955, 6,166,066 and 6,531,636; International Patent applications WO 01/9773, WO 97/29079, WO99/02499, WO 98/41519, and WO 94/12466; European Patent Nos. EP 0570920and EP 0444451; French Patent No. FR 2735774; and Israeli Pat. Nos. IL 01/00551 and IL 99/00187; Gaoni and Mechoulam, J. Amer. Chem. Soc. 93, 217 (1971); Mechoulam et al., Science 169, 611 (1970); Edery et al., Ann. N.Y. Acad. Sci., 191,40 (1971); Mechoulam et al., J. Amer. Chem. Soc., 94,7930 (1972); R. Mechoulam (ed.), “Marijuana: Chemistry, Metabolism, Pharmacology, and Clinical Effects” Academic Press, 1973, New-York; Houry et al., J. Med. Chem., 17,287 (1974); Houry et al., J. Med. Chem., 18, 951(1975); Mechoulam et al., Chem. Reviews, 76,75 (1976); Mechoulam et al., J. Med. Chem., 23, 1068 (1980); Srebnik et al., J. Chem. Soc., Perkin-Trans.I, 2881 (1984); Mechoulam et al., Tetrahedron: Asymmetry, 1, 315 (1990); Devane et al., Science, 258,1946 (1992); Burstein et al., J. Med. Chem., 35, 3135 (1992); Hanus et al., J. Med. Chem., 36, 3032 (1993); Mechoulam et, al., Biochem. Pharmacol., 50, 83 (1995); Sheskin et al., J. Med. Chem., 40, 659 (1997); Rhee et al., J. Med. Chem. 40, 3228 (1997); and Hanus et al., PNAS, 98, 3662 (2001).
U.S. Pat. Nos.
4,371,720, 5,013,387, 5,081,122, 5,292,736, 5,461,034, 5,618,955, 6,166,066 and 6,531,636; International Patent applications WO 01/9773, WO 97/29079, WO99/02499, WO 98/41519, and WO 94/12466; European Patent Nos. EP 0570920and EP 0444451; French Patent No. FR 2735774; and Israeli Pat. Nos. IL 01/00551 and IL 99/00187; Gaoni and Mechoulam, J. Amer. Chem. Soc. 93, 217 (1971); Mechoulam et al., Science 169, 611 (1970); Edery et al., Ann. N.Y. Acad. Sci., 191,40 (1971); Mechoulam et al., J. Amer. Chem. Soc., 94,7930 (1972); R. Mechoulam (ed.), “Marijuana: Chemistry, Metabolism, Pharmacology, and Clinical Effects” Academic Press, 1973, New-York; Houry et al., J. Med. Chem., 17,287 (1974); Houry et al., J. Med. Chem., 18, 951(1975); Mechoulam et al., Chem. Reviews, 76,75 (1976); Mechoulam et al., J. Med. Chem., 23, 1068 (1980); Srebnik et al., J. Chem. Soc., Perkin-Trans.I, 2881 (1984); Mechoulam et al., Tetrahedron: Asymmetry, 1, 315 (1990); Devane et al., Science, 258,1946 (1992); Burstein et al., J. Med. Chem., 35, 3135 (1992); Hanus et al., J. Med. Chem., 36, 3032 (1993); Mechoulam et, al., Biochem. Pharmacol., 50, 83 (1995); Sheskin et al., J. Med. Chem., 40, 659 (1997); Rhee et al., J. Med. Chem. 40, 3228 (1997); and Hanus et al., PNAS, 98, 3662 (2001).